Revive Therapeutics (RVV) AI Stock Analysis

• Market Cap: C$25.11M
• Dividend Yield: N/A
• Average Volume (3M): 285.50K
• Price to Earnings (P/E): ―
• Beta (1Y): -1.61
• Revenue Growth: N/A
• EPS Growth: -80.42%
• Country: CA
• Employees: 2
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): >-0.01
• Shares Outstanding: 418,564,270
• 10 Day Avg. Volume: 295,136
• 30 Day Avg. Volume: 285,498
• PEG Ratio: >-0.01
• Price to Book (P/B): -2.43
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -10.39
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 47 Neutral
• Price Target: C$0.06 ▲(490.00% Upside)
• Action: Reiterated Date: 03/14/26
• Date: Action: Reiterated 03/14/26

The score is primarily held back by weak financial performance (no revenue, ongoing losses, negative equity and reduced asset base). Technicals provide some support due to strong price trends and positive MACD, but overbought momentum signals increase near-term risk. Valuation is also constrained by a negative P/E and no provided dividend yield.

Positive Factors

Low absolute debt

Very low absolute debt reduces near-term interest and principal servicing burdens and lowers immediate default risk. For a clinical-stage developer this preserves optionality to prioritize R&D spend or negotiate partnerships rather than dedicating cash to debt service, aiding multi-month program continuity.

Reduced cash burn versus prior years

Material reduction in operating and free cash outflows versus earlier multi‑million burn demonstrates improved cost discipline and a smaller ongoing financing gap. Sustained lower burn extends runway, reduces frequency of dilutive raises and gives more time to reach clinical de‑risking milestones over the next several months.

Clinical‑stage, focused pipeline

A concentrated clinical-stage pipeline in psychedelics and repurposing targets growing therapeutic areas and can attract milestone-based collaborations or licensing. Proprietary and in‑licensed assets provide multiple non‑dilutive funding pathways and potential commercial upside if near‑term development objectives are met.

Negative Factors

No revenue and large trailing losses

Absence of revenue and substantial trailing losses mean the business lacks operating cash generation and must rely on external capital to sustain development. Over a 2–6 month horizon this elevates financing risk and could delay programs if milestone achievement does not unlock funding or partnerships.

Negative shareholders' equity and collapsed assets

A sharp decline in assets and negative equity materially weakens balance sheet resilience. This structural deterioration limits borrowing capacity, reduces strategic flexibility, and increases counterparty caution—raising the risk that the company may need dilutive financing or asset sales to continue operations.

Not self‑funding; dependence on external capital

Persistent negative operating cash flow and limited asset reserves create ongoing dependence on equity raises, partnerships or licensing to fund trials. That reliance can delay programs, constrain negotiating leverage, and lead to dilution or repricing of strategic transactions over the medium term.

Revive Therapeutics Business Overview & Revenue Model

Company Description

Revive Therapeutics Ltd., a life sciences company, focuses on the research and development of therapeutics for rare disorders and infectious diseases. The company offers cannabinoid pharmaceutical portfolio that focuses on rare inflammatory diseases. It is developing Bucillamine, which is in Phase 3 clinical study for the treatment of infectious diseases, including influenza and COVID-19; Psilocybin that is in Phase 1 clinical study for treating methamphetamine use disorder; Psilocin for the treatment of depression, anxiety, bi-polar disorder, bulimia and anorexia nervosa, and other diseases; and cannabidiol for treating autoimmune hepatitis and ischemia and reperfusion injury from organ transplantation. Revive Therapeutics Ltd. has research collaboration agreements with PharmaTher Inc. for the development of psilocybin in the treatment of cancer and the discovery of other uses of undisclosed psychedelic compounds; North Carolina State University for the development of a biosynthetic version of psilocybin based on a natural biosynthesis enzymatic platform; the University of California, San Francisco to explore the use of Bucillamine as a treatment for severe COVID-19; University of Health Sciences Antigua for the clinical research of psychedelics; and PharmaTher for the development of psilocybin microneedle patch. The company was incorporated in 2012 and is headquartered in Toronto, Canada.

How the Company Makes Money

null

Revive Therapeutics Financial Statement Overview

Summary

Financials reflect a non-revenue, loss-making profile with ongoing cash burn. While absolute debt is very low, the sharp drop in assets and the shift to negative equity materially weaken the balance sheet and increase financing risk.

Income Statement

TTM (Trailing-Twelve-Months) shows no revenue and continued losses, with net income at about -$10.8M and negative gross profit, indicating the company is still in a pre-commercial or non-revenue stage. Losses improved materially versus FY2024 (net loss about -$5.6M) and remain below the much larger losses seen in FY2021–FY2022, but profitability and margin profile are still weak given the lack of revenue base.

Balance Sheet

Leverage is modest in absolute dollars (TTM total debt about $68K), but the balance sheet quality has deteriorated sharply as stockholders’ equity turned negative (about -$3.5M in TTM and FY2025) versus positive equity in FY2024 and earlier. Total assets are also much smaller (about $0.25M TTM vs ~$10.6M in FY2024), reducing financial flexibility and increasing dependence on external funding.

Cash Flow

Cash burn continues: TTM operating cash flow and free cash flow are both about -$0.44M, and FY2025 free cash flow was about -$0.81M. While cash burn is far lower than FY2021–FY2023 levels (multi-million annual outflows), TTM free cash flow declined versus the prior period (negative growth), and the business is not self-funding given persistent negative operating cash flow.

Breakdown	Sep 2025	Sep 2024	Sep 2023	Sep 2022	Sep 2021
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00
Gross Profit	-248.00	-328.00	-434.00	-578.00	-775.00
EBITDA	-11.01M	-5.60M	-5.52M	-17.74M	-18.57M
Net Income	-11.01M	-5.62M	-6.32M	-17.83M	-20.20M
Balance Sheet
Total Assets	205.02K	10.64M	14.25M	17.07M	29.81M
Cash, Cash Equivalents and Short-Term Investments	24.56K	773.07K	2.09M	3.92M	16.60M
Total Debt	66.87K	25.22K	219.69K	327.73K	415.84K
Total Liabilities	3.66M	3.40M	3.60M	4.46M	999.68K
Stockholders Equity	-3.46M	7.23M	10.65M	12.60M	28.81M
Cash Flow
Free Cash Flow	-807.66K	-3.29M	-6.03M	-13.06M	-11.31M
Operating Cash Flow	-807.66K	-3.29M	-6.03M	-13.06M	-8.31M
Investing Cash Flow	-30.00K	0.00	0.00	0.00	-2.72M
Financing Cash Flow	39.15K	1.98M	4.20M	376.35K	26.24M

Revive Therapeutics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.01
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Negative
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:RVV, the sentiment is Positive. The current price of 0.01 is below the 20-day moving average (MA) of 0.02, below the 50-day MA of 0.02, and below the 200-day MA of 0.02, indicating a bullish trend. The MACD of <0.01 indicates Negative momentum. The RSI at 79.57 is Negative, neither overbought nor oversold. The STOCH value of 83.33 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:RVV.

Revive Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
MVMD	49 Neutral	C$8.81M	-1.56	-461.32%	―	-46.59%	8.26%
RVV	47 Neutral	C$25.11M	-4.56	899.59%	―	―	-80.42%
RAMM	46 Neutral	C$1.79M	-0.20	-82.37%	―	-15.51%	-49.26%
PCLO	44 Neutral	C$10.00M	5.19	―	―	15.64%	58.47%
AYUR	40 Underperform	C$1.95M	-1.54	-271.33%	―	15.95%	-1.81%

Revive Therapeutics Corporate Events

Revive Extends Bucillamine Patent Shield Across Nerve-Agent and Infectious Disease Uses

Revive Therapeutics has expanded its intellectual property portfolio around bucillamine by filing U.S. and Canadian patent applications covering the use of the drug to treat victims exposed to chemical warfare nerve agents, while also securing a Canadian patent for its use in treating or preventing infectious diseases such as influenza and COVID-19. The company says these moves deepen long-term exclusivity for one of its key pipeline assets and position bucillamine as a versatile platform across infectious disease, public-health emergencies and government-funded medical countermeasures, supporting potential opportunities in biodefense stockpiling, future partnerships and broader applications including organophosphate poisoning and traumatic brain injury.

The most recent analyst rating on (TSE:RVV) stock is a Hold with a C$0.02 price target. To see the full list of analyst forecasts on Revive Therapeutics stock, see the TSE:RVV Stock Forecast page.

Revive Therapeutics Updates on Nerve Agent Countermeasure Study

Revive Therapeutics has announced an update on its research study evaluating Bucillamine as a potential treatment for nerve agent exposure, in collaboration with Defence R&D Canada. The study is expected to conclude in January 2026, with findings to be released upon authorization from DRDC. This collaboration highlights Revive’s strategic focus on developing medical countermeasures and could enhance its positioning in the life sciences industry.